- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Expanded indication for MS treatment granted
Interferon beta-1b (Betaseron, Berlex) can now be prescribed to patients with multiple sclerosis who have experienced a first clinical episode and have MRI features consistent with MS. The new approval was based on findings from BENEFIT, a study of patients experiencing their first clinical demyelinating event. Results showed the drug delayed time to a second event by one year compared with placebo. Betaseron is also indicated for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacist-Led Intervention Could Help Lower Rates of Inappropriate Aspirin Use
December 5th 2023Updated guidance from the United States Preventive Services Task Force advises against low-dose aspirin use as a primary prevention of atherosclerotic cardiovascular disease in certain populations who have bleeding risks.
